Blinatumomab antibody molecule, artwork

Blinatumomab antibody molecule, artwork

C029/1342 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 74.4MB

Downloadable file size: 1.4MB

Price image Pricing

Please login to use the price calculator


Caption: Schematic computer artwork of the monoclonal antibody Blinatumomab, a bi-specific T-cell engager (BiTE). Blinatumomab (trade name) specifically targets the CD19 antigen present on B cells. Blinatumomab enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor. The drug works by linking these two cell types and activating the T cell to exert cytotoxic activity on the target cell.Blinatumomab is used as a second-line treatment against acute lymphoblastic leukemia.

Release details: Model release not required. Property release not required.

Keywords: activating, activity, acute, adult, antibodies, antibody, antigen, artwork, bi-specific, bites, blinatumomab, cancer, cd19, cd3, cell, cells, combines, cytotoxic, drug, illustration, leukemia, linking, lymphoblastic, malignant, molecule, monoclonal, patients, pediatric, potential, receptor, second-line, t cells, t-cell engagers, target, therapeutic, treatment, tumor, tumour, two binding sites

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.